New Therapeutic Strategies for Lewy Body Dementias

Overview

Journal Curr Neurol Neurosci Rep

Specialty Neurology

Date 2017 Jul 26

PMID 28741230

Citations 12

Authors

Latha Velayudhan

Dominic Ffytche

Clive Ballard

Dag Aarsland

Affiliations

Soon will be listed here.

Abstract

This article reviews current treatment strategies and recent advances for the Lewy body dementias (LBDs). Current available symptom treatment strategies are based on monoaminergic, cholinergic and glutaminergic neurotransmitter systems. Relatively robust evidence exists for cholinesterase inhibitors for cognitive impairment in LBD and in Parkinson's disease for antidepressants, clozapine and recently pimavanserin for psychosis. interpidine (RVT 101) and nelotanserin are currently under investigation. Non-pharmacological interventions, such as cognitive stimulation, physical exercises and neuromodulation strategies, may be useful in Parkinson's disease but have not yet been tested in dementias. Disease-modifying approaches are aimed at preventing, slowing or ameliorating the production, aggregation and deposition of pathological proteins, including immunotherapy targeting α-synuclein and an ongoing trial using ambroxol which increases glucocerebrosidase activity to lower the levels of the protein alpha-synuclein. Other disease-modifying clinical trials are using agents to augment insulin signalling, stem cell therapy, reducing amyloid pathology and gene therapy.

Citing Articles

Treatment of dementia: recommendations of the Scientific Department of Cognitive Neurology and Aging of the Brazilian Academy of Neurology.

Caramelli P, Marinho V, Laks J, Coletta M, Stella F, Camargos E Dement Neuropsychol. 2022; 16(3 Suppl 1):88-100.

PMID: 36533154 PMC: 9745994. DOI: 10.1590/1980-5764-DN-2022-S106PT.

RENEWAL: REpurposing study to find NEW compounds with Activity for Lewy body dementia-an international Delphi consensus.

OBrien J, Chouliaras L, Sultana J, Taylor J, Ballard C Alzheimers Res Ther. 2022; 14(1):169.

PMID: 36369100 PMC: 9650797. DOI: 10.1186/s13195-022-01103-7.

The Role of Glial Mitochondria in α-Synuclein Toxicity.

Jeon Y, Kwon Y, Jo M, Lee S, Kim S, Kim H Front Cell Dev Biol. 2020; 8:548283.

PMID: 33262983 PMC: 7686475. DOI: 10.3389/fcell.2020.548283.

Antibody Fragments as Tools for Elucidating Structure-Toxicity Relationships and for Diagnostic/Therapeutic Targeting of Neurotoxic Amyloid Oligomers.

Bitencourt A, Campos R, Cline E, Klein W, Sebollela A Int J Mol Sci. 2020; 21(23).

PMID: 33255488 PMC: 7727795. DOI: 10.3390/ijms21238920.

Challenges and opportunities for improving the landscape for Lewy body dementia clinical trials.

Goldman J, Forsberg L, Boeve B, Armstrong M, Irwin D, Ferman T Alzheimers Res Ther. 2020; 12(1):137.

PMID: 33121510 PMC: 7597002. DOI: 10.1186/s13195-020-00703-5.

References

Ffytche D . Visual hallucinatory syndromes: past, present, and future. Dialogues Clin Neurosci. 2007; 9(2):173-89. PMC: 3181850. View

Martinez-Martin P, Reddy P, Katzenschlager R, Antonini A, Todorova A, Odin P . EuroInf: a multicenter comparative observational study of apomorphine and levodopa infusion in Parkinson's disease. Mov Disord. 2014; 30(4):510-6. DOI: 10.1002/mds.26067. View

Lefaucheur J . A comprehensive database of published tDCS clinical trials (2005-2016). Neurophysiol Clin. 2016; 46(6):319-398. DOI: 10.1016/j.neucli.2016.10.002. View

Aarsland D . Cognitive impairment in Parkinson's disease and dementia with Lewy bodies. Parkinsonism Relat Disord. 2015; 22 Suppl 1:S144-8. DOI: 10.1016/j.parkreldis.2015.09.034. View

Walker Z, Possin K, Boeve B, Aarsland D . Lewy body dementias. Lancet. 2015; 386(10004):1683-97. PMC: 5792067. DOI: 10.1016/S0140-6736(15)00462-6. View

Stoeckel L, Arvanitakis Z, Gandy S, Small D, Kahn C, Pascual-Leone A . Complex mechanisms linking neurocognitive dysfunction to insulin resistance and other metabolic dysfunction. F1000Res. 2016; 5:353. PMC: 4897751. DOI: 10.12688/f1000research.8300.2. View

Rockenstein E, Desplats P, Ubhi K, Mante M, Florio J, Adame A . Neuropeptide Treatment with Cerebrolysin Enhances the Survival of Grafted Neural Stem Cell in an α-Synuclein Transgenic Model of Parkinson's Disease. J Exp Neurosci. 2016; 9(Suppl 2):131-40. PMC: 4938121. DOI: 10.4137/JEN.S25521. View

Pollak P, Tison F, Rascol O, Destee A, Pere J, Senard J . Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow up. J Neurol Neurosurg Psychiatry. 2004; 75(5):689-95. PMC: 1763590. DOI: 10.1136/jnnp.2003.029868. View

Banerjee S, Hellier J, Romeo R, Dewey M, Knapp M, Ballard C . Study of the use of antidepressants for depression in dementia: the HTA-SADD trial--a multicentre, randomised, double-blind, placebo-controlled trial of the clinical effectiveness and cost-effectiveness of sertraline and mirtazapine. Health Technol Assess. 2013; 17(7):1-166. PMC: 4782811. DOI: 10.3310/hta17070. View

10.

Fan X, Jin W, Lu J, Wang J, Wang Y . Rapid and reversible knockdown of endogenous proteins by peptide-directed lysosomal degradation. Nat Neurosci. 2014; 17(3):471-80. PMC: 3937121. DOI: 10.1038/nn.3637. View

11.

Ballard C, Isaacson S, Mills R, Williams H, Corbett A, Coate B . Impact of Current Antipsychotic Medications on Comparative Mortality and Adverse Events in People With Parkinson Disease Psychosis. J Am Med Dir Assoc. 2015; 16(10):898.e1-7. DOI: 10.1016/j.jamda.2015.06.021. View

12.

Meltzer H, Mills R, Revell S, Williams H, Johnson A, Bahr D . Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson's disease psychosis. Neuropsychopharmacology. 2009; 35(4):881-92. PMC: 3055369. DOI: 10.1038/npp.2009.176. View

13.

Takahashi S, Mizukami K, Yasuno F, Asada T . Depression associated with dementia with Lewy bodies (DLB) and the effect of somatotherapy. Psychogeriatrics. 2009; 9(2):56-61. DOI: 10.1111/j.1479-8301.2009.00292.x. View

14.

Himeno E, Ohyagi Y, Ma L, Nakamura N, Miyoshi K, Sakae N . Apomorphine treatment in Alzheimer mice promoting amyloid-β degradation. Ann Neurol. 2011; 69(2):248-56. DOI: 10.1002/ana.22319. View

15.

Aarsland D, Creese B, Politis M, Chaudhuri K, Ffytche D, Weintraub D . Cognitive decline in Parkinson disease. Nat Rev Neurol. 2017; 13(4):217-231. PMC: 5643027. DOI: 10.1038/nrneurol.2017.27. View

16.

Bogaerts V, Engelborghs S, Kumar-Singh S, Goossens D, Pickut B, van der Zee J . A novel locus for dementia with Lewy bodies: a clinically and genetically heterogeneous disorder. Brain. 2007; 130(Pt 9):2277-91. DOI: 10.1093/brain/awm167. View

17.

Elder G, Firbank M, Kumar H, Chatterjee P, Chakraborty T, Dutt A . Effects of transcranial direct current stimulation upon attention and visuoperceptual function in Lewy body dementia: a preliminary study. Int Psychogeriatr. 2015; 28(2):341-7. PMC: 4720143. DOI: 10.1017/S1041610215001180. View

18.

Olanow C, Brundin P . Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?. Mov Disord. 2013; 28(1):31-40. DOI: 10.1002/mds.25373. View

19.

Cummings J, Isaacson S, Mills R, Williams H, Chi-Burris K, Corbett A . Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet. 2013; 383(9916):533-40. DOI: 10.1016/S0140-6736(13)62106-6. View

20.

Strouwen C, Molenaar E, Keus S, Munks L, Munneke M, Vandenberghe W . Protocol for a randomized comparison of integrated versus consecutive dual task practice in Parkinson's disease: the DUALITY trial. BMC Neurol. 2014; 14:61. PMC: 3974198. DOI: 10.1186/1471-2377-14-61. View